- AuthorisedPhase I and Phase II (Integrated)- First administration to humans
A double-blind, randomised, placebo-controlled, first-in-human (FIH) Phase I/IIa, multi-centre trial to assess safety, tolerability, and immune response of single and multiple ascending doses of TOL2 (Immune Tolerising Agent) in patients with generalised myasthenia gravis
This study is testing a new medicine, TOL2, for generalised myasthenia gravis. It's looking at how safe the medicine is, how well people can tolerate it, and if it affects the body's immune system. This is an early-stage UK trial.
For: generalised myasthenia gravisGermany · Denmark · Sweden - Ongoing, recruitingTherapeutic exploratory (Phase II)
A phase 2, randomised, double-blind, placebo-controlled trial to evaluate safety and local tolerability of four weekly administrations of A24110He in subjects with elevated triglyceride plasma concentrations
This study is testing a new medicine called A24110He for people with very high levels of a type of fat (triglycerides) in their blood. We want to see if it's safe and how the body handles it. Participants will receive either the new medicine or a dummy treatment (placebo).
For: Moderate to severe hypertriglyceridemiaSweden - Ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Phase 1b, Double-blind, Placebo-controlled, Randomised Trial Investigating the Effect of AZD3427 on Renal Perfusion in HFrEF Patients With Renal Impairment Using Positron Emission Tomography (PET)
This study is looking at a new medicine called AZD3427 for people with heart failure and kidney problems. It uses special scans to see if the medicine improves blood flow in the kidneys over 8 days. Doctors want to know if it's safe and how well it helps.
For: Heart failure with reduced ejection fraction · Renal impairmentSweden